Effect of Probiotics (Vivomixx®) on Weight, Microbiota and Glucose Tolerance in Obese Pregnant Women and Their Newborn
Launched by HVIDOVRE UNIVERSITY HOSPITAL · Jul 24, 2015
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
Accumulating evidence indicates that the gut microbiota plays a significant role in obesity and because the "ideal" composition of the gut microbiota remains poorly understood, modulation of the gut microbiota composition represents a potentially attractive treatment option against excessive gestational weight gain and adverse outcomes for obese pregnant women and their newborn. Dietary supplements in the form of probiotics could be an efficient treatment for controlling weight gain in pregnancy by inducing changes in the gut microbiota and could have influence on infant's microbiota, which...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • BMI ≥ 30 and ≤35 kg/m2- calculated from pre-pregnancy weight
- • Primiparous singleton pregnancy
- • Able to read and speak Danish
- • Normal ultrasound scan of the fetus at gestational age 12-14
- • Oral glucose tolerance test at gestational age 14-20
- Exclusion Criteria:
- • Pregnancy at \> 20 weeks gestation at recruitment
- • Pre-gestational diabetes or other serious diseases
- • Multiple pregnancy
- • Previous bariatric surgery
- • Ingestion of probiotics \< 1 month before the inclusion or ingestion of other kinds of probiotics than the study probiotics
About Hvidovre University Hospital
Hvidovre University Hospital is a leading clinical research institution located in Denmark, dedicated to advancing medical science through rigorous clinical trials and innovative healthcare solutions. As a prominent academic hospital, it integrates patient care with research, fostering collaboration among multidisciplinary teams of healthcare professionals, researchers, and academic institutions. Hvidovre University Hospital is committed to enhancing patient outcomes by conducting high-quality clinical studies across various therapeutic areas, ensuring adherence to ethical standards and regulatory compliance. Its state-of-the-art facilities and focus on translational medicine position the hospital as a key player in the development of new treatments and therapies, ultimately contributing to the improvement of public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hvidovre, Copenhagen, Denmark
Patients applied
Trial Officials
Andreas M Petersen, MD, PhD
Principal Investigator
Hvidovre University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials